Clinical Trial Update: Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating rasburicase for prevention and treatment of hyperuricemia in pediatric patients with non-Hodgkin's lymphoma and acute leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rasburicase (rasburicase)

Snippet

Sponsor: Sanofi | Conditions: Lymphoma | Phase 4 | Status: COMPLETED